<em>Targeted Oncology</em>, a print and digital resource that offers content and expert opinions on precision medicine in oncology, launched its second “Expert Perspective: Virtual Tumor Board” on Wednesday, September 12. The Virtual Tumor Board is a video-editorial board discussion that features key opinion leaders from a specific oncological field. This episode will focus on non–small cell lung cancer.
Targeted Oncology™, a print and digital resource that offers content and expert opinions on precision medicine in oncology, launched its second “Expert Perspective: Virtual Tumor Board” on Wednesday, September 12. The Virtual Tumor Board is a video-editorial board discussion that features key opinion leaders from a specific oncological field. This episode will focus on nonsmall cell lung cancer.
“We look forward to launching the next Virtual Tumor Board on nonsmall cell lung cancer on September 12,” said Michael J. Hennessy Jr., president of MJH Associates Inc., parent company of Targeted Oncology. “Through this ongoing initiative, we can gather different key opinion leaders each time and really make an impact in the oncology community providing the latest updates from their specific field of practice.”
The Virtual Tumor Board will feature several thoracic oncologists and pathologist professionals that will provide an in-depth analysis on four patients with nonsmall cell lung cancer, biomarker testing and treatment strategies from a collaborative medical setting. Together, these experts will provide a focused look at multiple case sets from a treatment team perspective to further educate community-based oncologists in this comprehensive series of practice-changing insights.
The key opinion leaders participating in this Virtual Tumor Board:
About Targeted Oncology
Amivantamab/Lazertinib Still Effective in EGFRm NSCLC Despite Dose Interruptions
March 26th 2024According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
Read More
Newer TKIs Show Better Intracranial Responses in ROS1+ NSCLC
March 13th 2024In the first article of a 2-part series, Christine Bestvina, MD, discussed the role of the newer tyrosine kinase inhibitor repotrectinib for patients with non–small cell lung cancer that is positive for a ROS1 mutation.
Read More